Neuroendocrine Tumors Therapeutics Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00 – $ 8,900.00

Global Neuroendocrine Tumors Therapeutics Market By Drug Class (Somatostatin Analogues,(Octreotide, Lanreotide, Pasireotide), Chemotherapeutics (Fluorouracil (5-FU), Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil), Streptozocin, Temozolomide (Temodar), Capecitabine (Xeloda), Dacarbazine (DTIC), Oxaliplatin (Eloxatin)), Targeted Therapeutics, (Sunitinib, Everolimus,Others)), By Indication (Lung NET, Others NET, Gastrointestinal NET, Pancreatic NET), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography

Request Sample

Request Methodology

Request Sample

$ PRICE - $ 3,000.00 – $ 8,900.00

Clear selection

Description
Table Of Content
Company Profile

Report

Description

The global Neuroendocrine Tumors Therapeutics Market is expected to grow at a CAGR of 9.5% during the forecast period 2022 to 2028. Neuroendocrine tumors (NET) are the abnormal growths which begin in neuroendocrine cells. Neuroendocrine which are similar to the nerve cells and hormones producing cells. Neuroendocrine tumors are rare and can occur anywhere in the body. Most neuroendocrine tumors occur in the small intestine, lungs, rectum, appendix, and pancreas. Neuroendocrine tumors can be noncancerous (benign) or cancerous (malignant). NETs will arises from several neuroendocrine cells whose normal functions are to serve at neuroendocrine interface. Neuroendocrine cells will present throughout the body where hormones are produced but not only in the endocrine glands. Neuroendocrine tumors therapeutics market expected to grow owing to increase in initiatives taken by various international organizations like American Association for Cancer Research and World Health Organization to treat neuroendocrine tumors are expected to drive the growth of the market. AACR provided $250,000 fund for the Prevention of neuroendocrine tumors. Rise in health care expenditure, increase in prevalence rate of neuroendocrine tumors in developing regions is anticipated to drive global neuroendocrine tumors market. Though the market is expected to witness healthy growth, lack of skilled healthcare professional and lower adoption of advanced treatment technologies in the developing economies are key restraints for neuroendocrine tumors market.

Neuroendocrine Tumors Therapeutics Market

MARKET SUMMARY

9.5% CAGR

Study Period– 2022 – 2028
Base Year– 2021
CAGR– 9.5%
Largest Market– North-America
Fastest Growing Market– Europe

Neuroendocrine Tumors Therapeutics Market

The global Neuroendocrine Tumors Therapeutics Market report gives comprehensive outlook on Neuroendocrine Tumors Therapeutics Market across the globe with special emphasis on key regions such as Asia Pacific, North America, Europe, Latin America, and Middle East and Africa.
The report on global Neuroendocrine Tumors Therapeutics Market gives historical, current, and future market sizes (US$ Mn) on the basis of drug class, indication, distribution channel and Region.

Key Players

Pfizer
Eli Lilly & Company
Novartis AG
F. Hoffmann-La Roche
Ipsen

Dynamics

Neuroendocrine Tumors Therapeutics Market

The neuroendocrine tumors treatment market is expected to gain steady traction in the foreseeable future as there are many novel drugs are in pipeline. Increase in NET incidence and prevalence globally. As per the estimation of Canadian Cancer Society (CCS), about 315 individuals were diagnosed with endocrine cancers in 2012 in Canada and rate is raising with early stage diagnosis and migration. Moreover, rise in survival rate of neuroendocrine tumors by treating with various medications are expected to have a positive impact on neuroendocrine tumors market. According to the study published in the JAMA Oncology Journal (2017), the survival rate for all neuroendocrine tumour treatment have improved, especially for distant-stage gastrointestinal neuroendocrine tumour treatment and pancreatic neuroendocrine tumour treatment.

North-America got significant share

Neuroendocrine Tumors Therapeutics Market

Based on the geographical regions, global neuroendocrine tumors therapeutics market is segmented into five key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. According to Cancer.Net, approximately 8,000 people are identified with neuroendocrine cancer every year in the U.S. Several key players functioning in neuroendocrine tumors therapeuticsare based in the U.S. Hence, in North America became main market for product launch and research and development activities. Furthermore, entrenched infrastructure and favorable reimbursement scenario are the major factors accountable for the strengthening of North America’s neuroendocrine tumors therapeutics market. Europe is the second largest market for neuroendocrine tumors therapeutics, followed by Asia-Pacific. Increase in prevalence of neuroendocrine cancer in Asia-Pacific along with the refining economic scenario is expected to play an important role in driving the market growth in the region.

Latin-America

North-America

Europe

Asia-Pacific

Middle East

Key

Features of the Report

The report provides granular level information about the market size, regional market share and forecast
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Neuroendocrine Tumors Therapeutics Market Segmentation

Drug Class

Somatostatin Analogues
- Octreotide
- Lanreotide
- Pasireotide
Chemotherapeutics
- Fluorouracil (5-FU)
- Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)
- Streptozocin
- Temozolomide (Temodar)
- Capecitabine (Xeloda)
- Dacarbazine (DTIC)
- Oxaliplatin (Eloxatin)
Targeted Therapeutics
- Sunitinib
- Everolimus
Others

Indication

Lung NET
Others NET
Gastrointestinal NET
Pancreatic NET

Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Report

Table Of Content

1. Executive summary

2. Global Neuroendocrine Tumors Therapeutics Market Introduction

2.1. Global Neuroendocrine Tumors Therapeutics Market – Taxonomy

2.2. Global Neuroendocrine Tumors Therapeutics Market –Definitions

2.2.1. Drug Class

2.2.2. Indication

2.2.3. Distribution Channel

3.Global Neuroendocrine Tumors Therapeutics Market Dynamics

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Neuroendocrine Tumors Therapeutics Market Dynamics – Factors Impact Analysis

3.6. Global Neuroendocrine Tumors Therapeutics Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Neuroendocrine Tumors Therapeutics Market – Product Innovations

4. Global Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. Global Neuroendocrine Tumors Therapeutics Market, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024

5.1. Somatostatin Analogues

5.1.1. Octreotide

5.1.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.1.3. Market Opportunity Analysis

5.1.2. Lanreotide

5.1.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.2.3. Market Opportunity Analysis

5.1.3. Pasireotide

5.1.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.3. Market Opportunity Analysis

5.2. Chemotherapeutics

5.2.1. Fluorouracil (5-FU)

5.2.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.1.3. Market Opportunity Analysis

5.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

5.2.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.2.3. Market Opportunity Analysis

5.2.3. Streptozocin

5.2.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.3.3. Market Opportunity Analysis

5.2.4. Capecitabine (Xeloda)

5.2.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.4.3. Market Opportunity Analysis

5.2.5. Dacarbazine (DTIC)

5.2.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.5.3. Market Opportunity Analysis

5.2.6. Temozolomide (Temodar)

5.2.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.6.3. Market Opportunity Analysis

5.2.7. Oxaliplatin (Eloxatin)

5.2.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.7.3. Market Opportunity Analysis

5.3. Targeted Therapeutics

5.3.1. Sunitinib

5.3.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.3.1.3. Market Opportunity Analysis

5.3.2. Everolimus

5.3.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.3.2.3. Market Opportunity Analysis

5.4. Others

5.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.4.3. Market Opportunity Analysis

6. Global Neuroendocrine Tumors Therapeutics Market Forecast, By Indication, 2013 – 2017 and Forecast, 2018 – 2024

6.1. Lung NET

6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.1.3. Market Opportunity Analysis

6.2. Gastrointestinal NET

6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.2.3. Market Opportunity Analysis

6.3. Pancreatic NET

6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.3.3. Market Opportunity Analysis

6.4. Others

6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

6.4.3. Market Opportunity Analysis

7. Global Neuroendocrine Tumors Therapeutics Market Forecast, By Distribution Channel , 2013 – 2017 and Forecast, 2018 – 2024

7.1. Retail Pharmacies

7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.1.3. Market Opportunity Analysis

7.2. Hospital Pharmacies

7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.2.3. Market Opportunity Analysis

7.3. Others

7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

7.3.3. Market Opportunity Analysis

8. Global Neuroendocrine Tumors Therapeutics Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024

8.1. North America

8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.1.3. Market Opportunity Analysis

8.2. Europe

8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.5.3. Market Opportunity Analysis

8.6. Global Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Class, Indication, Distribution Channel and Region, 2018 – 2024

9. North America Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

9.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1.1. Somatostatin Analogues

9.1.1.1.1. Octreotide

9.1.1.1.2. Lanreotide

9.1.1.1.3. Pasireotide

9.1.1.2. Chemotherapeutics

9.1.1.2.1. Fluorouracil (5-FU)

9.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

9.1.1.2.3. Streptozocin

9.1.1.2.4. Temozolomide (Temodar)

9.1.1.2.5. Capecitabine (Xeloda)

9.1.1.2.6. Dacarbazine (DTIC)

9.1.1.2.7. Oxaliplatin (Eloxatin)

9.1.1.3. Targeted Therapeutics

9.1.1.3.1. Sunitinib

9.1.1.3.2. Everolimus

9.1.1.4. Others

9.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1. Lung NET

9.1.2.2. Others NET

9.1.2.3. Gastrointestinal NET

9.1.2.4. Pancreatic NET

9.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Retail Pharmacies

9.1.3.2. Hospital Pharmacies

9.1.3.3. Others

9.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. US

9.1.4.2. Canada

9.1.5. North America Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel, and Country, 2018 – 2024

9.1.6. North America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

10. Europe Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

10.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Somatostatin Analogues

10.1.1.1.1. Octreotide

10.1.1.1.2. Lanreotide

10.1.1.1.3. Pasireotide

10.1.1.2. Chemotherapeutics

10.1.1.2.1. Fluorouracil (5-FU)

10.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

10.1.1.2.3. Streptozocin

10.1.1.2.4. Temozolomide (Temodar)

10.1.1.2.5. Capecitabine (Xeloda)

10.1.1.2.6. Dacarbazine (DTIC)

10.1.1.2.7. Oxaliplatin (Eloxatin)

10.1.1.3. Targeted Therapeutics

10.1.1.3.1. Sunitinib

10.1.1.3.2. Everolimus

10.1.1.4. Others

10.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Lung NET

10.1.2.2. Others NET

10.1.2.3. Gastrointestinal NET

10.1.2.4. Pancreatic NET

10.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Retail Pharmacies

10.1.3.2. Hospital Pharmacies

10.1.3.3. Others

10.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Germany

10.1.4.2. UK

10.1.4.3. France

10.1.4.4. Spain

10.1.4.5. Italy

10.1.4.6. Russia

10.1.4.7. Poland

10.1.4.8. Rest of Europe

10.1.5. Europe Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024

10.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

11. Asia-Pacific Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

11.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Somatostatin Analogues

11.1.1.1.1. Octreotide

11.1.1.1.2. Lanreotide

11.1.1.1.3. Pasireotide

11.1.1.2. Chemotherapeutics

11.1.1.2.1. Fluorouracil (5-FU)

11.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

11.1.1.2.3. Streptozocin

11.1.1.2.4. Temozolomide (Temodar)

11.1.1.2.5. Capecitabine (Xeloda)

11.1.1.2.6. Dacarbazine (DTIC)

11.1.1.2.7. Oxaliplatin (Eloxatin)

11.1.1.3. Targeted Therapeutics

11.1.1.3.1. Sunitinib

11.1.1.3.2. Everolimus

11.1.1.4. Others

11.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Lung NET

11.1.2.2. Others NET

11.1.2.3. Gastrointestinal NET

11.1.2.4. Pancreatic NET

11.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Retail Pharmacies

11.1.3.2. Hospital Pharmacies

11.1.3.3. Others

11.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

11.1.4.1. Japan

11.1.4.2. China

11.1.4.3. India

11.1.4.4. ASEAN

11.1.4.5. Australia & New Zealand

11.1.4.6. Rest of Asia-Pacific

11.1.5. Asia-Pacific Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024

11.1.6. Europe Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

12. Latin America Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

12.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Somatostatin Analogues

12.1.1.1.1. Octreotide

12.1.1.1.2. Lanreotide

12.1.1.1.3. Pasireotide

12.1.1.2. Chemotherapeutics

12.1.1.2.1. Fluorouracil (5-FU)

12.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

12.1.1.2.3. Streptozocin

12.1.1.2.4. Temozolomide (Temodar)

12.1.1.2.5. Capecitabine (Xeloda)

12.1.1.2.6. Dacarbazine (DTIC)

12.1.1.2.7. Oxaliplatin (Eloxatin)

12.1.1.3. Targeted Therapeutics

12.1.1.3.1. Sunitinib

12.1.1.3.2. Everolimus

12.1.1.4. Others

12.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Lung NET

12.1.2.2. Others NET

12.1.2.3. Gastrointestinal NET

12.1.2.4. Pancreatic NET

12.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Retail Pharmacies

12.1.3.2. Hospital Pharmacies

12.1.3.3. Others

12.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Brazil

12.1.4.2. Mexico

12.1.4.3. Argentina

12.1.4.4. Venezuela

12.1.4.5. Rest of Latin America

12.1.5. Latin America Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index, By Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024

12.1.6. Latin America Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

13. Middle East and Africa Neuroendocrine Tumors Therapeutics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024

13.1.1. Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Somatostatin Analogues

13.1.1.1.1. Octreotide

13.1.1.1.2. Lanreotide

13.1.1.1.3. Pasireotide

13.1.1.2. Chemotherapeutics

13.1.1.2.1. Fluorouracil (5-FU)

13.1.1.2.2. Doxorubicin (Adriamycin) or liposomal doxorubicin (Doxil)

13.1.1.2.3. Streptozocin

13.1.1.2.4. Temozolomide (Temodar)

13.1.1.2.5. Capecitabine (Xeloda)

13.1.1.2.6. Dacarbazine (DTIC)

13.1.1.2.7. Oxaliplatin (Eloxatin)

13.1.1.3. Targeted Therapeutics

13.1.1.3.1. Sunitinib

13.1.1.3.2. Everolimus

13.1.1.4. Others

13.1.2. Indication Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. Lung NET

13.1.2.2. Others NET

13.1.2.3. Gastrointestinal NET

13.1.2.4. Pancreatic NET

13.1.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Retail Pharmacies

13.1.3.2. Hospital Pharmacies

13.1.3.3. Others

13.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.4.1. Gulf Cooperation Council (GCC) Countries

13.1.4.2. Israel

13.1.4.3. South Africa

13.1.4.4. Rest of MEA

13.1.5. MEA Neuroendocrine Tumors Therapeutics Market – Opportunity Analysis Index by Drug Analysis, Indication, Distribution Channel and Country, 2018 – 2024

13.1.6. MEA Neuroendocrine Tumors Therapeutics Market Dynamics – Trends

14. Competition Landscape

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Pfizer Inc., (U.S)

14.2.2. Eli Lilly & Company (U.S.)

14.2.3. Novartis AG (Switzerland)

14.2.4. F. Hoffmann-La Roche Ltd. (Switzerland)

14.2.5. Ipsen (France)

14.2.6. Amgen, Inc. (U.S.)

14.2.7. Teva Pharmaceuticals, Ltd. (Israel)

14.2.8. Bristol-Myers Squibb (U.S.)

15. Research Methodology

16. Key Assumptions and Acronyms

Description

search

Description

Neuroendocrine Tumors Therapeutics Market

Neuroendocrine Tumors Therapeutics Market

Neuroendocrine Tumors Therapeutics Market

Features of the Report

Neuroendocrine Tumors Therapeutics Market Segmentation

Drug Class

Indication

Distribution Channel

GEOGRAPHY

Frequently Asked Questions

Table Of Content

Company Profile

Description

Product categories

Our Clients

ASIA PACIFIC OFFICE

EUROPE OFFICE